ReviewInfectious diseases and therapy2026
Narrative Review of Two-Drug Regimens in Modern HIV Care: Driving Innovation, Flexibility, and Quality of Life.
Review in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment goals in human immunodeficiency virus (HIV) care have expanded beyond virological suppression to encompass long-term tolerability, treatment satisfaction, adherence, quality of life and person-centred care. Within this evolving framework, two-drug regimens (2DRs) with oral and long-acting drugs have emerged as an important therapeutic strategy, demonstrating high virological efficacy in selected clinical settings, while reducing cumulative drug exposure and expanding treatment options. Dolutegravir/lamivudine, dolutegravir/rilpivirine and long-acting cabotegravir/rilpivirine are the regimens studied the most, supported by randomised trials and real-world evidence. Beyond efficacy, 2DRs can improve flexibility of care, support adherence, reduce treatment burden and positively affect patient-reported outcomes. Long-acting injectable strategies may be particularly valuable for individuals who face challenges with daily oral adherence or treatment-related stigma. This narrative review summarizes current evidence on the role of oral and injectable 2DRs in key domains including innovation, flexibility, tolerability, adherence and quality of life, while discussing current limitations and future perspectives.
Indexed as
Identifiers
42728470What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.